** Shares of Cidara Therapeutics CDTX.O edge lower after hours as co looks to capitalize on big pop in its stock to raise equity
** CDTX shares soared ~114% to close at $44.95, nearly 4-yr high, after co early Mon announced positive topline results from Phase II trial for CD388, a non-vaccine preventative of seasonal influenza
** Co said study met primary and secondary efficacy endpoints for all dose groups
** After the bell, San Diego-based firm commenced $250 mln stock offering
** JP Morgan, Morgan Stanley, Guggenheim and Cantor are jt bookrunners
** Cidara has ~13 mln shares outstanding for current market cap of roughly $580 mln, per recent 10-Q filing
** Through Fri close, CDTX shares had lost ~22% in 2025
** All 7 analysts are bullish on CDTX with median PT of $56.50, up from $40 a month ago, latest LSEG data shows
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。